首页> 美国卫生研究院文献>International Journal of Clinical and Experimental Medicine >Combined treatment for cutaneous Rosai-Dorfman disease: a report of 2 cases
【2h】

Combined treatment for cutaneous Rosai-Dorfman disease: a report of 2 cases

机译:皮肤Rosai-Dorfman病联合治疗2例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

We report 2 cases of cutaneous Rosai-Dorfman disease (CRDD). One was a 46-year-old Chinese woman who presented with a 10-year history of multiple papules and nodules on the left cheek. Another one was a 57-year-old Chinese woman who presented with a 7-month history of erythematous pruritic plaque on the Dorsum nasi. Their lesions consisted of proliferative large histiocytes occasionally showing emperipolesis. Immunohistochemistry showed these histiocytes were positive for CD68 and S-100, but negative for CD1a. A diagnosis of CRDD was made. Their lesions were improved after intralesional treatment with Compound Betamethasone, interferon and acitretin. To our knowledge, we for the first time reported the application of intralesional Compound Betamethasone and Lidocaine, intramuscular injection of interferon, and oral acitretin in the treatment of CRDD, and favorable outcome was achieved without recurrence over a 1-year follow-up period.
机译:我们报告了2例皮肤Rosai-Dorfman病(CRDD)。一名是46岁的中国妇女,有10年的左颊多发丘疹和结节病史。另一位是一名57岁的中国妇女,她在Dorsum nasi上出现了7个月的红斑性瘙痒斑块病史。它们的病变由偶尔显示经验性极少的增生性大组织细胞组成。免疫组织化学显示这些组织细胞对CD68和S-100呈阳性,但对CD1a呈阴性。诊断为CRDD。用复方倍他米松,干扰素和阿维A进行病灶内治疗后,病灶得到改善。据我们所知,我们首次报道了病灶内化合物倍他米松和利多卡因的应用,肌内注射干扰素和口服阿维A酸在CRDD的治疗,并且在1年的随访期内无复发获得了良好的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号